非小細胞肺がん（NSCLC）の世界市場：2025年

非小細胞肺がん（NSCLC）の市場規模は、今後数年間で急成長が見込まれます。2029年にはCAGR10.5％で332億9,000万米ドルに成長すると予測されています。予測期間の成長は、新たな併用療法、人工知能（AI）の統合、個別化ワクチンの拡大、研究における世界の共同研究、患者中心の医療に起因しています。予測期間における主な動向には、がん医療における遠隔医療の統合、リキッドバイオプシー技術、診断技術の進歩、低侵襲手術技術の採用、免疫チェックポイント阻害剤などがあります。

タバコ消費率の上昇が、今後数年間の非小細胞肺がん（NSCLC）市場の成長を牽引すると予想されます。タバコの消費とは、一般的に喫煙、チューイング、スナッフィングなどによる個人のタバコ製品の使用を指し、ニコチンやその他の化学物質を体内に取り込みます。タバコの煙には、肺細胞のDNA（デオキシリボ核酸）を傷つけ、突然変異や、非小細胞肺がん（NSCLC）を含むがん細胞の制御不能な増殖につながる数多くの発がん性物質が含まれています。例えば、米国に本部を置く連邦政府機関である米国食品医薬品局（USFDA）が発表した2024年全米青少年たばこ調査によると、2024年10月、全生徒の1.1％（約225万人）が現在たばこ製品を使用していると回答しました。この中には、高校生の10.1％（約158万人）、中学生の5.4％（約64万人）が含まれており、さらに、可燃性タバコ製品のいずれかを現在使用していると回答した生徒は2.8％（約76万人）、複数のタバコ製品を使用していると回答した生徒は3.0％（約84万人）でした。その結果、タバコ消費率の上昇が非小細胞肺がん（NSCLC）市場の成長に拍車をかけています。

非小細胞肺がん（NSCLC）市場の予想成長は、大気汚染の増加によってさらに促進されます。大気汚染を構成する大気中の有害物質は人間の健康に悪影響を及ぼし、肺細胞の炎症、DNA損傷、突然変異を通じてNSCLCのリスクを高める可能性があります。世界保健機関（WHO）は2023年6月、大気汚染と家庭大気汚染が年間700万人の早死につながると報告しました。さらに、約24億人が危険なレベルの家庭大気汚染にさらされています。さらに世界銀行は2022年9月、大気汚染による健康被害は年間8兆1,000億ドルにのぼり、これは世界のGDPの6.1％に相当すると強調しました。したがって、非小細胞肺がん（NSCLC）の成長は、大気汚染の増加によって推進されると予想されます。

当レポートは、世界の非小細胞肺がん（NSCLC）市場について調査し、市場の概要とともに、タイプ別、治療法別、流通チャネル別、タイプ別、地域・国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 非小細胞肺がん（NSCLC）市場の特徴

第3章 非小細胞肺がん（NSCLC）市場の動向と戦略

第4章 非小細胞肺がん（NSCLC）市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界非小細胞肺がん（NSCLC）の成長分析と戦略分析フレームワーク

• 世界の非小細胞肺がん（NSCLC）PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の非小細胞肺がん（NSCLC）市場の成長率分析
• 世界の非小細胞肺がん（NSCLC）の市場規模実績、2019年～2024年
• 世界の非小細胞肺がん（NSCLC）の市場規模と成長予測、2024年～2029年、2034年予想
• 世界の非小細胞肺がん（NSCLC）総獲得可能市場（TAM）

第6章 非小細胞肺がん（NSCLC）市場セグメンテーション

• 世界の非小細胞肺がん（NSCLC）市場、タイプ別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
• 扁平上皮がん
• 大細胞がん
• 腺がん
• その他
• 世界の非小細胞肺がん（NSCLC）市場、治療法別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
• 放射線治療
• レーザー治療
• 光線力学療法（PDT）
• その他
• 世界の非小細胞肺がん（NSCLC）市場、流通チャネル別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• オンライン薬局
• その他
• 世界の非小細胞肺がん（NSCLC）市場、扁平上皮がんのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年、2034年
• 角化扁平上皮がん
• 非角化性扁平上皮がん
• 世界の非小細胞肺がん（NSCLC）市場、大細胞がんのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
• 未分化大細胞がん
• 大細胞神経内分泌がん
• 世界の非小細胞肺がん（NSCLC）市場、腺がんのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
• 浸潤性腺がん
• 細気管支肺胞がん
• 世界の非小細胞肺がん（NSCLC）市場、その他のタイプのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
• 混合細胞型がん
• 肉腫様がん

第7章 非小細胞肺がん（NSCLC）市場の地域別および国別分析

• 世界の非小細胞肺がん（NSCLC）市場、地域別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
• 世界の非小細胞肺がん（NSCLC）市場、国別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測

第8章 アジア太平洋の非小細胞肺がん（NSCLC）市場

第9章 中国の非小細胞肺がん（NSCLC）市場

第10章 インドの非小細胞肺がん（NSCLC）市場

第11章 日本の非小細胞肺がん（NSCLC）市場

第12章 オーストラリアの非小細胞肺がん（NSCLC）市場

第13章 インドネシアの非小細胞肺がん（NSCLC）市場

第14章 韓国の非小細胞肺がん（NSCLC）市場

第15章 西欧の非小細胞肺がん（NSCLC）市場

第16章 英国の非小細胞肺がん（NSCLC）市場

第17章 ドイツの非小細胞肺がん（NSCLC）市場

第18章 フランスの非小細胞肺がん（NSCLC）市場

第19章 イタリアの非小細胞肺がん（NSCLC）市場

第20章 スペインの非小細胞肺がん（NSCLC）市場

第21章 東欧の非小細胞肺がん（NSCLC）市場

第22章 ロシアの非小細胞肺がん（NSCLC）市場

第23章 北米の非小細胞肺がん（NSCLC）市場

第24章 米国の非小細胞肺がん（NSCLC）市場

第25章 カナダの非小細胞肺がん（NSCLC）市場

第26章 南米の非小細胞肺がん（NSCLC）市場

第27章 ブラジルの非小細胞肺がん（NSCLC）市場

第28章 中東の非小細胞肺がん（NSCLC）市場

第29章 アフリカの非小細胞肺がん（NSCLC）市場

第30章 非小細胞肺がん（NSCLC）市場の競合情勢と企業プロファイル

• 非小細胞肺がん（NSCLC）市場の競合情勢
• 非小細胞肺がん（NSCLC）市場企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Merck &Co. Inc.
  • AbbVie Inc.
  • Novartis AG

第31章 非小細胞肺がん（NSCLC）市場その他の大手企業と革新的企業

• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Viatris Inc
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• UCB S.A.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited

第32章 世界の非小細胞肺がん（NSCLC）市場の競合ベンチマーキングとダッシュボード

第33章 非小細胞肺がん（NSCLC）市場における主要な合併と買収

第34章 非小細胞肺がん（NSCLC）市場の最近の動向

第35章 非小細胞肺がん（NSCLC）市場の潜在性が高い国、セグメント、戦略

• 2029年の非小細胞肺がん（NSCLC）市場- 最も新しい機会を提供する国
• 2029年の非小細胞肺がん（NSCLC）市場- 最も新しい機会を提供するセグメント
• 2029年の非小細胞肺がん（NSCLC）市場- 成長戦略
  • 市場動向に基づく戦略
  • 競合戦略

第36章 付録

Non-small cell lung cancer (NSCLC) is a form of epithelial lung cancer that originates in the lung tissues, marked by the abnormal proliferation of cells. The primary causes of NSCLC include long-term smoking, genetic mutations, exposure to air pollution, and secondhand smoke.

The main subtypes of non-small cell lung cancer (NSCLC) are squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and others. Squamous cell carcinoma originates from squamous epithelial cells and can manifest in various parts of the body. A variety of therapeutic approaches are employed for NSCLC, including radiotherapy, laser therapy, photodynamic therapy (PDT), and others. These therapeutic options are distributed through different channels, including hospital pharmacies, online pharmacies, and others.

The non-small cell lung cancer (NSCLC) market research report is one of a series of new reports from The Business Research Company that provides non-small cell lung cancer (NSCLC) market statistics, including non-small cell lung cancer (NSCLC) industry global market size, regional shares, competitors with a non-small cell lung cancer (NSCLC) market share, detailed non-small cell lung cancer (NSCLC) market segments, market trends and opportunities, and any further data you may need to thrive in the non-small cell lung cancer (NSCLC) industry. This non-small cell lung cancer (NSCLC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-small cell lung cancer (NSCLC) market size has grown rapidly in recent years. It will grow from $20.1 billion in 2024 to $22.35 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to evolution of immunotherapy, genomic profiling and precision medicine, expansion of clinical trials, smoking cessation initiatives.

The non-small cell lung cancer (NSCLC) market size is expected to see rapid growth in the next few years. It will grow to $33.29 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to emerging combination therapies, integration of artificial intelligence (AI), expansion of personalized vaccines, global collaborations in research, patient-centric care. Major trends in the forecast period include integration of telemedicine in oncology, liquid biopsy technologies, advances in diagnostic technologies, adoption of minimally invasive surgical techniques, immune checkpoint inhibitors.

The rising rate of tobacco consumption is anticipated to drive the growth of the non-small cell lung cancer (NSCLC) market in the coming years. Tobacco consumption refers to individuals' use of tobacco products, commonly through smoking, chewing, or snuffing, which introduces nicotine and other chemicals into the body. Tobacco smoke contains numerous carcinogens that can damage DNA (deoxyribonucleic acid) in lung cells, leading to mutations and the uncontrolled growth of cancerous cells, including non-small cell lung cancer (NSCLC). For instance, according to the 2024 National Youth Tobacco Survey published by the U.S. Food and Drug Administration (USFDA), a U.S.-based federal agency, in October 2024, 1.1% of all students (around 2.25 million) reported current tobacco product use. This included 10.1% of high school students (approximately 1.58 million) and 5.4% of middle school students (about 640,000) who reported using tobacco; additionally, 2.8% of students (around 760,000) reported current use of any combustible tobacco product, while 3.0% (about 840,000) reported using multiple tobacco products. Consequently, the rising rate of tobacco consumption is fueling growth in the non-small cell lung cancer (NSCLC) market.

The anticipated growth of the non-small cell lung cancer (NSCLC) market is further driven by increasing air pollution. Harmful substances in the atmosphere, constituting air pollution, can adversely affect human health, increasing the risk of NSCLC through inflammation, DNA damage, and mutations in lung cells. The World Health Organization reported in June 2023 that air and household air pollution were linked to 7 million premature deaths annually. Additionally, approximately 2.4 billion people are exposed to dangerous levels of household air pollution. The World Bank further highlighted in September 2022 that health damage from air pollution amounts to $8.1 trillion annually, equivalent to 6.1% of global GDP. Thus, the growth of non-small cell lung cancer (NSCLC) is expected to be propelled by increasing air pollution.

Major companies in the non-small cell lung cancer (NSCLC) market are strategically developing multiple treatment options, including monotherapy treatments, to gain a competitive advantage. Monotherapy treatment, utilizing a single drug or therapy to address medical disorders, provides a focused approach. For instance, in June 2022, Novartis AG gained approval from the European Commission for Tabrecta (capmatinib) to treat adult patients with advanced NSCLC with METex14 skipping. This targeted therapeutic option addresses mutations causing MET exon 14 (METex14) skipping.

In August 2022, Bristol-Myers Squibb's acquisition of Turning Point Therapeutics for $4.1 billion enhances its ability to treat ROS1-positive NSCLC patients with the promising therapy, repotrectinib, developed by Turning Point Therapeutics. Repotrectinib holds the potential to improve outcomes for patients with ROS1-positive non-small-cell lung cancer. Turning Point Therapeutics specializes in developing precision medicines for NSCLC.

Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (nsclc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the non-small cell lung cancer (nsclc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The non-small cell lung cancer (NSCLC) market includes revenues earned by entities by providing services such as targeted therapies, radiation therapies, imaging tests, biopsy, bronchoscopy, and lung function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-small cell lung cancer (NSCLC) market also includes sales of chemotherapy drugs such as cisplatin, carboplatin, and pemetrexed epidermal growth factor receptor (EGFR) inhibitors such as erlotinib, afatinib, and gefitinib, as well as pain medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-small cell lung cancer (nsclc) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-small cell lung cancer (nsclc) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-small cell lung cancer (nsclc) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Squamous Cell Carcinoma; Large Cell Carcinoma; Adenocarcinoma; Other Types
• 2) By Therapy: Radiotherapy; Laserthearpy; Photodynamic Therapy (PDT); Other Therapies
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Other Distribution Channels
• Subsegments:
• 1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma; Non-Keratinizing Squamous Cell Carcinoma
• 2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma; Large Cell Neuroendocrine Carcinoma
• 3) By Adenocarcinoma: Invasive Adenocarcinoma; Bronchioloalveolar Carcinoma
• 4) By Other Types: Mixed Cell Type Carcinoma; Sarcomatoid Carcinoma
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Small Cell Lung Cancer (NSCLC) Market Characteristics

3. Non-Small Cell Lung Cancer (NSCLC) Market Trends And Strategies

4. Non-Small Cell Lung Cancer (NSCLC) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Non-Small Cell Lung Cancer (NSCLC) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Small Cell Lung Cancer (NSCLC) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Small Cell Lung Cancer (NSCLC) Market Growth Rate Analysis
• 5.4. Global Non-Small Cell Lung Cancer (NSCLC) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Small Cell Lung Cancer (NSCLC) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Small Cell Lung Cancer (NSCLC) Total Addressable Market (TAM)

6. Non-Small Cell Lung Cancer (NSCLC) Market Segmentation

• 6.1. Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Adenocarcinoma
• Other Types
• 6.2. Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiotherapy
• Laserthearpy
• Photodynamic Therapy (PDT)
• Other Therapies
• 6.3. Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.4. Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Keratinizing Squamous Cell Carcinoma
• Non-Keratinizing Squamous Cell Carcinoma
• 6.5. Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Large Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Undifferentiated Large Cell Carcinoma
• Large Cell Neuroendocrine Carcinoma
• 6.6. Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Invasive Adenocarcinoma
• Bronchioloalveolar Carcinoma
• 6.7. Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mixed Cell Type Carcinoma
• Sarcomatoid Carcinoma

7. Non-Small Cell Lung Cancer (NSCLC) Market Regional And Country Analysis

• 7.1. Global Non-Small Cell Lung Cancer (NSCLC) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Small Cell Lung Cancer (NSCLC) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market

• 8.1. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Small Cell Lung Cancer (NSCLC) Market

• 9.1. China Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 9.2. China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Small Cell Lung Cancer (NSCLC) Market

• 10.1. India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Small Cell Lung Cancer (NSCLC) Market

• 11.1. Japan Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 11.2. Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Small Cell Lung Cancer (NSCLC) Market

• 12.1. Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market

• 13.1. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Small Cell Lung Cancer (NSCLC) Market

• 14.1. South Korea Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 14.2. South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market

• 15.1. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 15.2. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Small Cell Lung Cancer (NSCLC) Market

• 16.1. UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Small Cell Lung Cancer (NSCLC) Market

• 17.1. Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Small Cell Lung Cancer (NSCLC) Market

• 18.1. France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Small Cell Lung Cancer (NSCLC) Market

• 19.1. Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Small Cell Lung Cancer (NSCLC) Market

• 20.1. Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market

• 21.1. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 21.2. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Small Cell Lung Cancer (NSCLC) Market

• 22.1. Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Small Cell Lung Cancer (NSCLC) Market

• 23.1. North America Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 23.2. North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Small Cell Lung Cancer (NSCLC) Market

• 24.1. USA Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 24.2. USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Small Cell Lung Cancer (NSCLC) Market

• 25.1. Canada Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 25.2. Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Small Cell Lung Cancer (NSCLC) Market

• 26.1. South America Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 26.2. South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Small Cell Lung Cancer (NSCLC) Market

• 27.1. Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Small Cell Lung Cancer (NSCLC) Market

• 28.1. Middle East Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 28.2. Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Small Cell Lung Cancer (NSCLC) Market

• 29.1. Africa Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 29.2. Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Small Cell Lung Cancer (NSCLC) Market Competitive Landscape And Company Profiles

• 30.1. Non-Small Cell Lung Cancer (NSCLC) Market Competitive Landscape
• 30.2. Non-Small Cell Lung Cancer (NSCLC) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Non-Small Cell Lung Cancer (NSCLC) Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. GlaxoSmithKline Plc
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Viatris Inc
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Regeneron Pharmaceuticals Inc.
• 31.11. Astellas Pharma Inc.
• 31.12. UCB S.A.
• 31.13. Sun Pharmaceutical Industries Ltd.
• 31.14. Dr. Reddy's Laboratories Ltd.
• 31.15. Aurobindo Pharma Limited

32. Global Non-Small Cell Lung Cancer (NSCLC) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Small Cell Lung Cancer (NSCLC) Market

34. Recent Developments In The Non-Small Cell Lung Cancer (NSCLC) Market

35. Non-Small Cell Lung Cancer (NSCLC) Market High Potential Countries, Segments and Strategies

• 35.1 Non-Small Cell Lung Cancer (NSCLC) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Small Cell Lung Cancer (NSCLC) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Small Cell Lung Cancer (NSCLC) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer